Alnylam Pharmaceuticals
ALNY
#633
Rank
โ‚น2.808 T
Marketcap
โ‚น21,697
Share price
2.59%
Change (1 day)
74.89%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -โ‚น337.20

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -โ‚น357.80. In 2022 the company made an earnings per share (EPS) of -โ‚น808.74 a decrease over its 2021 EPS that were of -โ‚น626.80.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-โ‚น337.20-58.31%
2022-โ‚น808.7429.03%
2021-โ‚น626.80-3.36%
2020-โ‚น648.56-8.48%
2019-โ‚น708.637.67%
2018-โ‚น658.1439.74%
2017-โ‚น470.9712.94%
2016-โ‚น416.9938.84%
2015-โ‚น300.34-32.88%
2014-โ‚น447.46259.44%
2013-โ‚น124.49-31.25%
2012-โ‚น181.0752.94%
2011-โ‚น118.3930.77%
2010-โ‚น90.54-8.77%
2009-โ‚น99.2478.13%
2008-โ‚น55.72-70.78%
2007-โ‚น190.6599.09%
2006-โ‚น95.76-43.88%
2005-โ‚น170.63-82.33%
2004-โ‚น965.74-59.23%
2003-โ‚น2,369

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-โ‚น147.99-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3,252-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น681.64 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น23.50-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น147.12-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น325.59-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น276.86-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-โ‚น174.11-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel